MedPath

To evaluate the effect of Alpha lipoic acid on platelet aggregation in diabetic neuropathy patients

Not Applicable
Completed
Conditions
Health Condition 1: E114- Type 2 diabetes mellitus with neurological complications
Registration Number
CTRI/2022/02/040276
Lead Sponsor
Indian council of Medical Research
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
52
Inclusion Criteria

1.Type 2 diabetic patients of either sex aged between 30 - 65 years

2.Duration of diabetes >10 ± 5 years

3.Symptomatic diabetic polyneuropathy patients with VPT value more than 15V

4.HbA1c < 10%

5.Patients on stable dose of antidiabetic drug or combination of Metformin + sulphonyl urea +

DPP4 Inhibitors for the past 3 months

6.Patients on stable dose of Gabapentin 300 mg BD or Pregabalin 75mg BD for past 3 months

7.Serum creatinine < 2 mg/dl

Exclusion Criteria

1.Any other conditions causing neuropathic pain

2.History of hypersensitivity to alpha Lipoic acid

3.Patients on antiplatelet drugs

4.Patients receiving other antioxidants

5.Patients with active cardiovascular disease

6.Patients with liver dysfunction (ALT / AST > 3 times the upper limit of normal)

7.Patients with clinically significant skin disease

8.Pregnant and lactating women.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath